Nomura research report dated 12th Feb
Some snips
"The company recorded its highest-ever gross margin and EBITDA in the quarter."
"As per the company, almost one-third of sales in the US are from injectables. DRRD currently has five injectables on the market: Decitabine, Azacitadine, Fondaparinux, Gemcitabine and Zoledronic acid, which combined have contribute ~USD80mn in revenues in the quarter."
"We believe there is strong earnings support in the near term due to an extended period of low competition in specific products in the US"
http://breport.myiris.com/NFASIPL/DRREDLAB_20140212.pdf
Nomura research report dated 12th FebSome snips"The company...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable